Enanta Pharmaceuticals Inc ENTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
-
Enanta Pharmaceuticals to Participate in Investor Conferences in September
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
Trading Information
- Previous Close Price
- $11.19
- Day Range
- $11.05–11.49
- 52-Week Range
- $8.08–17.80
- Bid/Ask
- $10.39 / $12.50
- Market Cap
- $241.76 Mil
- Volume/Avg
- 132,058 / 176,878
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 145
- Website
- https://www.enanta.com
Comparables
Valuation
|
Metric
|
ENTA
|
AVIR
|
TVTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.59 | 0.59 | 68.90 |
Price/Sales | 3.28 | — | 5.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
ENTA
AVIR
TVTX
Financial Strength
|
Metric
|
ENTA
|
AVIR
|
TVTX
|
|---|---|---|---|
Quick Ratio | 4.65 | 18.87 | 2.89 |
Current Ratio | 4.92 | 19.02 | 3.04 |
Interest Coverage | −10.67 | — | −35.20 |
Quick Ratio
ENTA
AVIR
TVTX
Profitability
|
Metric
|
ENTA
|
AVIR
|
TVTX
|
|---|---|---|---|
Return on Assets (Normalized) | −20.47% | −23.62% | −9.03% |
Return on Equity (Normalized) | −46.81% | −25.11% | −47.00% |
Return on Invested Capital (Normalized) | −41.56% | −29.21% | −13.68% |
Return on Assets
ENTA
AVIR
TVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vbqmqrngz | Bndp | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bftfgrs | Ychxvlw | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fxqgvppw | Gslzqs | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yjptxks | Mbhwqq | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Ymqbkslq | Xsl | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Tvgsjsvxl | Njrj | $28.5 Bil | |||
| Moderna Inc
MRNA
| Kmwzpcvsg | Rps | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Jlvrhhwvg | Pnfd | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rhzyrscn | Crwvhws | $13.0 Bil | |||
| Incyte Corp
INCY
| Zfnnbqn | Txgtbz | $12.9 Bil |
United States